Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial-Reference-Cited by-同舟云学术

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial

Published:2024-08-22 Issue: Volume: Page:1-12
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Li Yingxin¹^ORCID,Young Na Joo²,Zhu Yunting³,Oh Jaeseong⁴,Zhao Amy⁵,Jang In-Jin⁶,Tang Lei⁷

Affiliation:

1. Translational Medicine and Clinical Pharmacology, Sanofi, Beijing, China

2. Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA

3. Pharmacokinetics, Dynamics and Metabolism, Sanofi, Beijing, China

4. Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, South Korea

5. Evidence Generation & Decision Science, Sanofi, Beijing, China

6. Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul, South Korea

7. Translational Medicine and Early Development, Sanofi, Suzhou, China

Funder

Sanofi

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2024.2394186

Reference25 articles.

1. The complement system

2. The complement system in the peripheral nerve: Friend or foe?

3. Complement in neurological disorders and emerging complement-targeted therapeutics

4. Complement System in Brain Architecture and Neurodevelopmental Disorders

5. Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s